Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea

Yacoub, Abdulraheem; Mascarenhas, John; Kosiorek, Heidi; T. Prchal, Josef; Berenzon, Dmitry; R. Baer, Maria; K. Ritchie, Ellen; T. Silver, Richard; M. Kessler, Craig; F. Winton, Elliott; Chiara Finazzi, Maria; Rambaldi, Alessandro; M. Vannucchi, Alessandro; Leibowitz, D; Rondelli, Damiano; O. Arcasoy, Murat; Catchatourian, Rosalind; Vadakara, Joseph; Rosti, Vittorio; O. Hexner, Elizabeth; Kremyanskaya, Marina; Sandy, Lonette; Tripodi, Joseph; Najfeld, Vesna; Farnoud, Noushin; Papaemmanuil, Elli; E. Salama, Mohamed; Singer-Weinberg, Rona; K. Rampal, Raajit; D. Goldberg, Judith; Barbui, Tiziano; A. Mesa, Ruben; C. Dueck, Amylou; Hoffman, Ronald

doi:10.1182/blood.2019000428

Public

Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea

Published in Blood • Sep 12, 2019

Authors:

Abdulraheem Yacoub

John Mascarenhas

Heidi Kosiorek

Abstract

Prior studies have reported high response rates with recombinant interferon-α (rIFN-α) therapy in patients with essential thrombocythemia (ET) and polycythemia vera (PV). To further define the role of rIFN-α, we investigated the outcomes of pegylated-rIFN-α2a (PEG) therapy in ET and PV patients prev...

Subject

Polycythemia vera

Medicine

Essential thrombocythemia

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!